Beryl Drugs Limited has announced that its promoter and director Mr. Sudhir Sethi has acquired additional equity shares in the company through market transactions. The latest acquisition was disclosed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, demonstrating continued regulatory compliance by the pharmaceutical company.

Latest Share Acquisition Details

The most recent transaction involved the acquisition of 7500 equity shares on 24-03-2026, representing 0.14% of the company's total share capital. The acquisition was executed through market transactions on BSE, with a total transaction value of ₹1,57,441, showing sustained investment by the promoter in the company's prospects.

Updated Shareholding Pattern

Following the latest acquisition, Mr. Sudhir Sethi's shareholding in Beryl Drugs Limited has increased significantly. His total holding has grown from 4,86,483 shares to 4,93,983 shares, reflecting his continued confidence in the company's growth trajectory.

SEBI Regulatory Compliance

The disclosure was made under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, with Mr. Sudhir Sethi identified as a Promoter and Director (DIN: 00090172). The company submitted the required disclosure to BSE Limited on 25-03-2026, ensuring transparency in insider trading activities. Managing Director Sanjay Sethi (DIN: 00090277) submitted the disclosure on behalf of the company.

Company Information

Beryl Drugs Limited, incorporated in 1993 and headquartered in Indore, Madhya Pradesh, continues to maintain its commitment to regulatory compliance and corporate governance standards. The company's registered office is located at Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.), with CIN: L02423MP1993PLC007840.

The disclosure demonstrates the company's adherence to SEBI regulations regarding insider trading requirements for promoters and directors. The acquisition reflects positive sentiment from the promoter group regarding the company's future prospects in the pharmaceutical sector.

Beryl drugs Limited has announced a board meeting scheduled for April 1, 2026, to deliberate on several important corporate governance matters. The meeting, set to commence at 11:00 AM at the company's registered office at 133, Kanchan Bagh, Indore 452001, will address key business decisions including director appointments and related party transactions.

Key Agenda Items

The board meeting will focus on eight primary business matters, with the most significant being the consideration and approval of an Extra Ordinary General Meeting (EOGM) notice. The EOGM will address critical appointments and transactions that require shareholder approval.

Director Appointments and Corporate Governance

The proposed EOGM will seek shareholder approval for regularizing Mr. Shailendra Pathak's appointment as Whole Time Director, including fixing his role, obligations, responsibilities, and remuneration. Additionally, the meeting will consider the appointment of Mrs. Neha Sarda as an Independent Director, strengthening the company's board composition.

A significant aspect of the agenda involves approving material related party transactions with M/s. Aminova Infusions P. Ltd., where Mr. Shailendra Pathak holds a directorship with 50% equity stake. This transaction requires proper disclosure and shareholder approval under regulatory requirements.

Administrative and Compliance Matters

The board will address several administrative functions essential for smooth operations. These include fixing the cut-off date and remote e-voting period for the EOGM, appointing Dipika Kataria as scrutinizer for e-voting processes, and authorizing directors to authenticate and file necessary forms under the Companies Act, 2013.

• Appointment of internal auditor for financial year 2026-2027 • General disclosures of directors' interests under section 184(1) • Authority to Mr. Sudhir Sethi for tender-related documentation • Consideration of additional resolutions with chair's permission

Meeting Details and Communication

The formal notice, dated March 20, 2026, was communicated to The Bombay Stock Exchange Limited as required under Regulation 29. Managing Director Sanjay Sethi (DIN: 00090272) signed the official communication, ensuring compliance with stock exchange notification requirements. The company has requested the exchange to take the information on record for further necessary actions.